StockData

Cellectis vs Lesaka Technologies

CLLS and LSAK side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CLLS and LSAK compare

Cellectis grew revenue faster over the last twelve months (75.8% versus 9.4% for Lesaka Technologies).

Lesaka Technologies keeps more of each dollar of sales as profit, with a net margin of 0.38% compared with −92.7% at Cellectis.

Lesaka Technologies scores higher on the StockData Score (6 against 3 for Cellectis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCLLSLSAK
Size and price
Market cap–$269M
Share price$0.921$3.14
Change, 1 year−79.1%−18.0%
Change, 5 years−89.4%−35.1%
Beta (5Y)2.120.56
Employees2293,900
StockData Score
Total score36 (better)
Valuation score01 (better)
Growth score22
Performance score11
Health score02 (better)
Dividend score00
Valuation
P/E–105×
P/S–0.4×
P/B–1.3×
EV/EBITDA–6.6×
P/FCF–8.5×
FCF yield–11.8%
Fair value–$1.96
Margin of safety–−60.4%
Growth
Revenue growth (TTM)75.8% (better)9.4%
Revenue growth, 5Y average7.4%40.7% (better)
Profitability
Gross margin100% (better)32.0%
Operating margin−45.3%1.8% (better)
Net margin−92.7%0.38% (better)
FCF margin−57.2%4.4% (better)
Return on equity−97.8%1.5% (better)
Return on invested capital−122%2.5% (better)
Financial health
Debt / equity–1.03
Net debt / EBITDA–2.15
Interest coverage−0.6×0.7× (better)
Current ratio–1.59
Altman Z-score–2.09
Piotroski F-score37 (better)
Dividends and buybacks
Buyback yield–0.13%
Shareholder yield–0.13%
Ownership
Held by institutions9.4%25.3%
Held by insiders53.4%11.8%
Insider net buying, 12 months–$5.7M
Short interest, % of float–0.56%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.